Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rallied.
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The post Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rallied. appeared first on Investor's Business Daily.
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.
The post Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rallied. appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
